A mechanistic classification of GNAO1 mutations links Gβ γ sequestration to hyperkinetic disease and treatment response

GNAO1 variants predicted to impair Gβγ release are significantly associated with NEDIM, and in GNAO1R209H/+ mice both caffeine and gallein reduce hyperlocomotion.

• Why it matters: Mechanistic links between specific GNAO1 mutation effects and involuntary-movement phenotypes are unclear, limiting targeted therapeutic guidance for NEDIM and related hyperkinetic disease.
• What they did: The study integrated human genetic analysis with cellular assays to classify variants into Gβγ-sequestering versus reduced Go-expression categories, then tested caffeine and gallein in the GNAO1R209H/+ mouse model using open-field behavior and whole-cell patch-clamp.
• The result: Mutations predicted to sequester Gβγ release associate with NEDIM, while treated GNAO1R209H/+ mice show significantly reduced hyperlocomotion and sex- and cell type-specific hyperexcitability in dorsolateral striatal spiny projection neurons.